

**Product Name** : CCX140

**Synonyms** : CCX-140; CCX 140; CCX140-B; CCX140B


**Cat No.** : M10382

**CAS Number** : 1100318-47-5

**Molecular Formula** : C<sub>20</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S

**Formula Weight** : 495.86

**Chemical Name** : Benzenesulfonamide, 4-chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)-



**Description** : A potent, selective, orally bioavailable CCR2 antagonist with K<sub>d</sub> of 2.3 nM for hCCR2; displays little to no activity against 142 various biologically important receptor, no effect on plasma levels of the CCR2 ligand CCL2 or on the numbers of blood monocytes; potently inhibits CCL2-induced chemotaxis of purified human blood monocytes with IC<sub>50</sub> of 8 nM, also inhibits CCL2-induced Ca<sup>2+</sup> mobilization in monocytes with IC<sub>50</sub> of 3 nM; decreases levels of fasting blood glucose and improves insulin sensitivity in mice. Diabetes Phase 2 Clinical

**Pathway** : GPCR/G Protein

**Target** : Chemokine Receptor

**Receptor** : Chemokine Receptor

**Solubility** : 10 mM in DMSO

**SMILES** : O=S(C1=CC=C(Cl)C(C(F)(F)F)=C1)(NC2=CC(C)=CN=C2C(C3=C4C(NC=C4)=NC=N3)=O)=O

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Sullivan TJ, et al. J Pharmacol Exp Ther. 2012 Jun 5. doi: 10.1124/jpet.111.190918. | 2. Sullivan TJ, et al. Metabolism. 2013 Nov;62(11):1623-32. | 3. Sullivan T, et al. Am J Physiol Renal Physiol. 2013 Nov 1;305(9):F1288-97.